Merck KGaA subsidiary tests blockchain for drug discovery, genomic data

Nebula Genomics announced June 11 its partnership with EMD Serono, the biopharmaceutical business of Merck KGaA in Darmstadt, Germany, for a pilot projected aimed at developing new medicines.

EMD Serono will use Nebula Genomics' database of anonymized genomic data, which is stored on a blockchain, to analyze what causes diseases. Further, the collaboration is designed to accelerate scientific discovery and drug development.

Nebula Genomics is building a platform that connects patients and consumers with researchers and incentivizes data sharing. The genomics company uses blockchain technology to allow patients to control who can access their genomic data. Patients are then paid with cryptocurrency for contributing to research.

By using blockchain technology, Nebula Genomics hopes to drive more participation in biomedical research.

More articles on health IT:
FDA clears 1st nerve stimulation device for adolescent IBS pain
Cleveland Clinic study finds electronic inhaler usage reduces COPD-related hospitalizations
Most health system CFOs lack agreeable cooperation with CIOs, survey finds

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers